OOIR: Observatory of International Research

Papers

(The H4-Index of SLAS Discovery is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones	160
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery	120
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors	50
Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations	49
A Critical and Concise Review of Mass Spectrometry Applied to Imaging in Drug Discovery	42
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2	38
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response	37
Cryo-EM: The Resolution Revolution and Drug Discovery	37
Phenotypic Profiling of Reference Chemicals across Biologically Diverse Cell Types Using the Cell Painting Assay	36
Recommended Guidelines for Developing, Qualifying, and Implementing Complex In Vitro Models (CIVMs) for Drug Discovery	34
High-Throughput Mass Spectrometry for Hit Identification: Current Landscape and Future Perspectives	32
High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids	31
Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry	30
Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3	29
Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries	26
Identification of Compounds for Butyrylcholinesterase Inhibition	26
Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery	25
A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19	24
Target Validation Using PROTACs: Applying the Four Pillars Framework	24
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery	23
A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19	22
Target-Directed Approaches for Screening Small Molecules against RNA Targets	22
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2	22